Roman Fabbricatore

The guideline update follows the FDA’s approval of imetelstat in patients with lower-risk MDS based on data from the phase 3 IMerge trial.

The safety profile of BNT111 plus cemiplimab was consistent with previous trials assessing BNT111 with anti–PD-L1 treatments.

Mismatched unrelated donor consideration may expand donor numbers, especially for those with minority ancestry seeking hematopoietic cell transplantation.

Age and racial differences in subgroup analyses emphasize the need for strategies addressing Alzheimer’s/dementia risk factors and prevention of breast cancer.

Multiple confirmed responses in a phase 2 trial support the FDA designation for the experimental therapy in squamous cell carcinoma of the head and neck.

Results from a phase 1 trial evaluating the CAR T-cell therapy, AIC100, in relapsed/refractory thyroid cancer support the FDA’s RMAT designation.

Following rare CRS and ICANS incidence following CAR T-cell therapy, investigators propose a reduced 2-week monitoring period with extensions as needed.

As of data cutoff, 6 patients with NSCLC in the phase 2 THIO-101 trial are receiving ongoing treatment with THIO plus cemiplimab after 12 months.

An observed extension in progression-free survival with nintedanib vs placebo did not warrant continued development of the therapy for thyroid cancer.

Findings from the PREVENT study show that bioimpedance spectroscopy use may reduce progression to chronic lymphedema compared with tape measure use.

A combined genomic and histological analysis within trial datasets demonstrates a sound tumor evaluation strategy for patients with prostate cancer.

Survival results from the phase 3 CheckMate –9DW trial support the application for the combination therapy in treating hepatocellular carcinoma.

Precision therapies for lung cancer may be improved by targeting RPL13A and GNL3, potentially indicative biomarkers of PD-1 inhibitor resistance.

Two dose-limiting toxicities were observed, and the maximum tolerated dose was not reached in a study evaluating FS-1502 safety, tolerability, and efficacy.

The recommendation was made following mid-stage, end-of-phase 2 data for the botensilimab/balstilimab combination, which yielded lower responses in patients.

Phase 1 data show that EMI-137 enabled MFGI and spectroscopy differentiation between papillary thyroid cancer–afflicted tissue and healthy thyroid tissue.

The drug developers of tabelecleucel are seeking approval of the treatment for patients with EBV-positive post-transplant lymphoproliferative disease.

The overall survival benefit seen with DOC1021 in a phase 1 trial of glioblastoma support the fast track status decision for the agent.

“The machine learning algorithms based on pure clinical data aren’t any better, [but] that’s where prostate cancer algorithms are starting to shine,” said James B. Yu, MD, MHS, FASTRO.

Retrospective results found considering conservative initial surgery options can reduce overtreatment for patients with thyroid cancer.

A serious grade 4 adverse effect reported in the phase 1/2 dose-escalation study evaluating seclidemstat combination therapy prompted the partial hold.

Phase 3 results show that treatment with vandetanib had no statistically significant improvement in PFS and more adverse effects than placebo.

The use of an ultrasensitive assay was able to detect HPV-16-positive SiHa cells at greater than 500 cells/mL for cervical cancer.

The results of the trial showed that at least 75% of patients with NSCLC harboring driver gene alterations may benefit from this treatment.

Results from the phase 2b TACTI-003 trial show that eftilagimod alfa plus pembrolizumab achieved high objective response and disease control rates.

Results from a retrospective cohort study display evidence of potential benefit from GLP-1RAs for the reduction of 13 obesity-associated cancers for those with type 2 diabetes.

Findings from the phase 3 FLAURA2 trial support the European approval of osimertinib/chemotherapy in EGFR-mutated non–small cell lung cancer.

Fertility and sexual health services appear to be offered to cancer survivors less often than other services at CoC-accredited practices.

A statistically significant and clinically meaningful improvement in progression-free survival in the phase 3 trial DUO-E support the recommendation.